key: cord-0783007-fd20kyds authors: Bamford, Connor G. G. title: Two courses of deconstructed coronavirus please date: 2021-04-29 journal: PLoS Pathog DOI: 10.1371/journal.ppat.1009547 sha: 518aba347eb9140f8a8723b3301f6e720a4e6ac2 doc_id: 783007 cord_uid: fd20kyds nan replication, and assembly. Construction of a full-length SARS-CoV-2 DNA clone allowed the deletion of its N gene and replacement with a reporter gene green fluorescent protein (GFP) to measure infection. Provision of N "in trans" in a stable cell line rescues N-deficient virus. This provided N cannot be incorporated back into the genome and so infection is limited to a single round or replication, which is enough to find antiviral molecules. As safety in working with SARS-CoV-2 is paramount, to reduce the potential even further for the N gene to recombine, Ju and colleagues utilised intein protein-splicing technology to effectively split N in 2 on independent genes. Although considered very unlikely, the only risk may be that while these modified viruses can still infect cells, coinfection in the respiratory tract of a worker carrying wild-type virus could provide opportunity for recombination and rescue of infectivity or that given the immense selection pressure, generation of N-like genetic novelty in vitro (as has been shown in E-deleted coronaviruses; [2] ) could facilitate rescued multicycle infection. Wild-type virus and gene-deleted viruses are produced through construction and manipulation of full-length virus genomes. Wild-type virus can infect any susceptible cells, and outcoming virus is fully infectious. However, gene-deleted viruses (loss of Nsp3, E, or N) can only replicate in cells providing the essential deleted gene products "in trans." Cells expressing the genes in trans will generally only be found within the lab, and not in somebody's respiratory tract, making these systems much safer and capable to be used outside of a BSL3 lab. Created with BioRender.com. BSL3, Biosafety Level 3; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2. https://doi.org/10.1371/journal.ppat.1009547.g001 Through the construction of their system, the Beijing-led team showed off their reagent to identify several effective antiviral drugs in vitro. Additionally, through reconstitution with distinct N genes, the group delineated the role of specific N features, such as the incompatibility between SARS-CoV-2 and N from the related Middle East Respiratory Syndrome Coronavirus (MERS-CoV), the critical role of specific N amino acid positions in promoting infection, and protein-protein interactions between N and host cell factors, rediscovering some previous identified interactions in other coronaviruses of animals [3] . Trans-complementation is a powerful technique in molecular virology to study basic biology and genetics. The system described in PLOS Pathogens here is not the only available system for SARS-CoV-2. Recently, Zhang and colleagues, from the lab of Pei-Yong Shi at the University of Texas Medical Branch, describe a similar reagent [4] . Unlike Ju and colleagues, the United States team removed 2 genes: "ORF3" and "E," which are then provided in trans. Zhang and colleagues looked closely at the safety profile, showing that the single-cycle viruses created were apathogenic in rodents. In the past, similar systems have been published for other coronaviruses too by the lab of Luis Enjuanes for MERS-CoV [5] and the porcine transmissible gastroenteritis coronavirus (TGEV) [6] . Furthermore, while a fantastic tool for discovery science, single-cycle viruses like these can be used as a safer vaccination tool such as has been used for Ebola [7] . Endeavours like those pursued by Ju and colleagues highlight the need and potential for the democratisation of science in the face of significant societal challenges, if reagents and protocols are indeed adequately shared. There are numerous examples of this in the scientific community, such as the generation and sharing of SARS-CoV-2 pseudoparticles from the lab of Benhur Lee [8] and the construction of a Coronavirus Disease 2019 (COVID-19) toolbox from the MRC-University of Glasgow Centre for Virus Research [9] . It is hoped that efforts like this will enhance the efficiency of science, while not jeopardising the safety of researchers and their communities. While enhancing sharing may make an impact during the COVID-19 pandemic, it is likely to have greater impact in the future, such as the "next big one" or slower crises like antimicrobial resistance. Every effort should be taken to encourage this behaviour for our own benefit. A novel cell culture system modeling the SARS-CoV-2 life cycle Identification of the Mechanisms Causing Reversion to Virulence in an Attenuated SARS-CoV for the Design of a Genetically Stable Vaccine The Cellular Interactome of the Coronavirus Infectious Bronchitis Virus Nucleocapsid Protein and Functional Implications for Virus Biology A trans-complementation system for SARS-CoV-2. bioRxiv Engineering a Replication-Competent, Propagation-Defective Middle East Respiratory Syndrome Coronavirus as a Vaccine Candidate Generation of a Replication-Competent, Propagation-Deficient Virus Vector Based on the Transmissible Gastroenteritis Coronavirus Genome Generation of biologically contained Ebola viruses Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera A plasmid DNAlaunched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research